Due to their unique mechanism of action, inhibitors of the sodium-glucose cotransporter type 2, in addition to glycemic and metabolic effects, have the ability to exert an inhibitory effect on various aspects of the pathogenesis of micro- and macrovascular complications of diabetes mellitus. Further large-scale clinical trials should provide information on which groups of patients with type 2 diabetes mellitus can benefit most from the administration of glyflozins while minimizing the risk of adverse events. Drugs such as BEVA22-2, SzK154 and SzK153 represented their mechanism and sidechains. Which lowers gastrointestinal side effects and improve patient adherence to drug regimens. In type 2 diabetic mice, dapagliflozin therapy reduces arterial stiffness, endothelial dysfunction, and vascular smooth muscle dysfunction, as well as changing the microbiota composition gradually. Collectively, the improvements in generalized vascular function may represent an important mechanism underlying the smooth muscle activity benefits of SGLT2 treatment.